InspireMD — Third Quarter 2026 Earnings Summary

InspireMD, Inc. reported a net loss of $9.76 million for the third quarter of 2026, driven by a decline in total revenue to $2.24 million due to a voluntary U.S. recall of its CGuard Prime delivery system. The company received FDA approval for its CGuard Prime TransCarotid Stent System for TCAR procedures, which is expected to expand its addressable market by over 35,000 annual procedures and commence U.S. sales in the fourth quarter of 2026. International revenue grew by 9.1% to $2.21 million, offsetting the loss of U.S. sales, while the company continues to advance its SwitchGuard neuroprotection system and plans to submit a PMA supplement for an enhanced CAS delivery system in December 2026.